Pieris Pharmaceuticals, Inc. Common Stock
PIRS US7207951036
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 38% | -73% | -83% | 7% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Jenkins George M |
20.13 USD |
2,500 Bought |
50,325 USD |
09/04/2025 | 09/04/2025 |
| Jenkins George M |
20.27 USD |
2,490 Bought |
50,472 USD |
09/04/2025 | 09/04/2025 |
| Jenkins George M |
12.93 USD |
4,000 Bought |
51,720 USD |
18/12/2024 | 18/12/2024 |
| Geraghty James A |
0.01 USD |
1 Sold |
0 USD |
12/12/2024 | 12/12/2024 |
| Geraghty James A |
1.00 USD |
1 Bought |
1 USD |
07/08/2024 | 07/08/2024 |